| Design, synthesis, docking, DFT, MD simulation studies of a new nicotinamide-based derivative: in vitro anticancer and VEGFR-2 inhibitory effects EB Elkaeed, RG Yousef, H Elkady, IMM Gobaara, BA Alsfouk, DZ Husein, ... Molecules 27 (14), 4606, 2022 | 79 | 2022 |
| Discovery of new quinoxaline-2 (1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation K El-Adl, HM Sakr, RG Yousef, ABM Mehany, AM Metwaly, ... Bioorganic Chemistry 114, 105105, 2021 | 67 | 2021 |
| New quinoxaline-2 (1 H)-ones as potential VEGFR-2 inhibitors: Design, synthesis, molecular docking, ADMET profile and anti-proliferative evaluations RG Yousef, HM Sakr, IH Eissa, ABM Mehany, AM Metwaly, ... New Journal of Chemistry 45 (36), 16949-16964, 2021 | 63 | 2021 |
| The Assessment of Anticancer and VEGFR-2 Inhibitory Activities of a New 1H-Indole Derivative: In Silico and In Vitro Approaches EB Elkaeed, RG Yousef, H Elkady, IMM Gobaara, AA Alsfouk, DZ Husein, ... Processes 10 (7), 1391, 2022 | 42 | 2022 |
| Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: Virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic … RG Yousef, A Ibrahim, MM Khalifa, WM Eldehna, IMM Gobaara, ... Journal of enzyme inhibition and medicinal chemistry 37 (1), 1389-1403, 2022 | 36 | 2022 |
| (E)-N-(3-(1-(2-(4-(2,2,2-Trifluoroacetamido)benzoyl)hydrazono)ethyl)phenyl)nicotinamide: A Novel Pyridine Derivative for Inhibiting Vascular Endothelial Growth … RG Yousef, H Elkady, EB Elkaeed, IMM Gobaara, HA Al-Ghulikah, ... Molecules 27 (22), 7719, 2022 | 35 | 2022 |
| New Anticancer Theobromine Derivative Targeting EGFRWT and EGFRT790M: Design, Semi-Synthesis, In Silico, and In Vitro Anticancer Studies EB Elkaeed, RG Yousef, H Elkady, AA Alsfouk, DZ Husein, IM Ibrahim, ... Molecules 27 (18), 5859, 2022 | 30 | 2022 |
| New theobromine derivative as apoptotic anti-triple-negative breast cancer targeting EGFR protein: CADD story IH Eissa, RG Yousef, H Elkady, EB Elkaeed, DZ Husein, IM Ibrahim, ... Journal of Molecular Structure 1294, 136336, 2023 | 27 | 2023 |
| Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies RG Yousef, A Elwan, IMM Gobaara, ABM Mehany, WM Eldehna, ... Journal of Enzyme Inhibition and Medicinal Chemistry 37 (1), 2206-2222, 2022 | 25 | 2022 |
| In silico, in vitro VEGFR-2 inhibition, and anticancer activity of a 3-(hydrazonomethyl)naphthalene-2-ol derivative EB Elkaeed, RG Yousef, H Elkady, ABM Mehany, BA Alsfouk, DZ Husein, ... Journal of Biomolecular Structure and Dynamics 41 (16), 7986-8001, 2023 | 24 | 2023 |
| Inhibition of vascular smooth muscle and cancer cell proliferation by new VEGFR inhibitors and their immunomodulator effect: Design, synthesis, and biological evaluation F Ran, W Li, Y Qin, T Yu, Z Liu, M Zhou, C Liu, T Qiao, X Li, RG Yousef, ... Oxidative medicine and cellular longevity 2021 (1), 8321400, 2021 | 24 | 2021 |
| Discovery of new VEGFR-2 inhibitors: design, synthesis, anti-proliferative evaluation, docking, and MD simulation studies EB Elkaeed, RG Yousef, MM Khalifa, A Ibrahim, ABM Mehany, ... Molecules 27 (19), 6203, 2022 | 21 | 2022 |
| Design, semi-synthesis, anti-cancer assessment, docking, MD simulation, and DFT studies of novel theobromine-based derivatives as VEGFR-2 inhibitors and apoptosis inducers IH Eissa, RG Yousef, H Elkady, EB Elkaeed, AA Alsfouk, DZ Husein, ... Computational Biology and Chemistry 107, 107953, 2023 | 12 | 2023 |
| A new anticancer semisynthetic theobromine derivative targeting EGFR protein: CADDD study IH Eissa, RG Yousef, H Elkady, AA Alsfouk, BA Alsfouk, DZ Husein, ... Life 13 (1), 191, 2023 | 11 | 2023 |
| A New Theobromine-Based EGFRWT and EGFRT790M Inhibitor and Apoptosis Inducer: Design, Semi-Synthesis, Docking, DFT, MD Simulations, and In Vitro … EB Elkaeed, RG Yousef, H Elkady, AA Alsfouk, DZ Husein, IM Ibrahim, ... Processes 10 (11), 2290, 2022 | 11 | 2022 |
| Design, synthesis, in silico and in vitro studies of new immunomodulatory anticancer nicotinamide derivatives targeting VEGFR-2 RG Yousef, WM Eldehna, A Elwan, AS Abdelaziz, ABM Mehany, ... Molecules 27 (13), 4079, 2022 | 11 | 2022 |
| Anticancer derivative of the natural alkaloid, theobromine, inhibiting EGFR protein: Computer-aided drug discovery approach IH Eissa, RG Yousef, EB Elkaeed, AA Alsfouk, DZ Husein, IM Ibrahim, ... Plos one 18 (3), e0282586, 2023 | 10 | 2023 |
| New quinoxalin‐2(1H)‐one‐derived VEGFR‐2 inhibitors: Design, synthesis, in vitro anticancer evaluations, in silico ADMET, and docking studies K El‐Adl, HM Sakr, RG Yousef, ABM Mehany, HS Abulkhair, IH Eissa Archiv der Pharmazie 355 (7), 2200048, 2022 | 8 | 2022 |
| Anti-breast cancer potential of a new xanthine derivative: in silico, antiproliferative, selectivity, VEGFR-2 inhibition, apoptosis induction and migration inhibition studies IH Eissa, RG Yousef, H Elkady, EB Elkaeed, BA Alsfouk, DZ Husein, ... Pathology-Research and Practice 251, 154894, 2023 | 7 | 2023 |
| A Theobromine Derivative with Anticancer Properties Targeting VEGFR‐2: Semisynthesis, in silico and in vitro Studies IH Eissa, RG Yousef, H Elkady, EB Elkaeed, AA Alsfouk, DZ Husein, ... ChemistryOpen 12 (10), e202300066, 2023 | 7 | 2023 |
